Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global COVID-19 antigen rapid test kits market was valued at USD 26.34 billion in 2024 and is projected to decline to USD 789 million by 2031, representing a compound annual growth rate (CAGR) of -40.3% during the forecast period. This significant decline is primarily attributed to the decline in COVID-19 cases globally and the subsequent reduction in testing requirements. However, certain segments continue to show resilience, particularly in regions with ongoing surveillance programs.
The COVID-19 Antigen Rapid Test Device is an in-vitro immunochromatographic assay for the qualitative detection of SARS-CoV-2 viral nucleoprotein antigens in nasopharyngeal swab, nasal swab, and oropharyngeal swab specimens from individuals suspected of COVID-19 by their healthcare provider. The primary function of these tests is to provide rapid results, typically within 15-30 minutes, making them crucial for mass screening efforts, especially in the earlier phases of the pandemic.
Market analysis indicates that the demand for these tests peaked during 2021-2022, with global revenues reaching an estimated USD 15-18 billion annually. However, as we move into 2024, the market has significantly contracted. The United States market size was estimated at USD 2.3 billion in 2024, while China's market reached approximately USD 1.8 billion. Other key markets include the European Union member states, Japan, and South Korea, though at much reduced levels compared to 2021-2022.
Market segmentation shows that the nasopharyngeal swab segment still accounts for the largest revenue share, expected to reach USD 780 million by 2031, despite declining at a CAGR of -35% over the next six years. This is because nasopharyngeal swabs remain the gold standard for sample collection in many clinical settings, though their use has declined significantly from the peak.
In terms of competitive landscape, the global market is led by several key players. Abbott Laboratories holds approximately 18% of the market share in terms of revenue, followed by QuidelOrtho (now part of QuidelOrtho Corporation) at 12%, and Roche Diagnostics at 10%. Other significant players include SD Biosensor, Siemens Healthineers, and Thermo Fisher Scientific. It's worth noting that over 150 companies obtained Emergency Use Authorization (EUA) from the FDA during the pandemic, though many have since exited the market or significantly reduced production.
Regional analysis shows that North America continues to be the largest market, accounting for approximately 38% of global demand, followed by Europe at 28% and Asia-Pacific at 25%. The market in Latin America and Middle East & Africa has seen the most significant decline, dropping by over 85% since 2022, primarily due to reduced testing capacity and transition to endemic disease management strategies.
The market's future trajectory will largely depend on several factors: the emergence of new variants requiring updated tests, government policies on ongoing surveillance, and the potential integration of these tests into broader respiratory disease panels. While the market is contracting, it's expected to stabilize at a lower baseline level as COVID-19 becomes endemic and testing becomes integrated into routine healthcare rather than emergency response.
Global Pandemic Response Acceleration
The unprecedented global demand for rapid COVID-19 detection has driven governments and private sectors to invest heavily in antigen test kits. With the World Health Organization recommending these tests for mass screening, countries worldwide are integrating them into their public health strategies.
Home Testing Revolution
As Omicron and subvariants continue to emerge, the convenience of at-home testing has created a new consumer market. Regulatory approvals for home-use antigen tests have increased by 240% in major markets, making them essential for pre-travel, event attendance, and family gatherings.
➤ Market analysts project the home testing segment to reach $12.8 billion by Q4 2023, with 67% of surveyed households indicating continued use of antigen tests for regular screening
The shift towards decentralized healthcare has further accelerated market growth, with pharmacies and online retailers reporting 320% increase in antigen test kit sales year-over-year.
MARKET CHALLENGES
Supply Chain Complexity
Global supply chain disruptions continue to affect raw material availability for test kit production. The specialized nitrocellulose membranes and conjugate pads require specific manufacturing conditions, with leading manufacturers reporting 30-45 day delays in component shipments. This has created bottlenecks in meeting the unprecedented global demand, particularly in developing regions.
Other Challenges
Regulatory Hurdles Across Regions
Divergent regulatory frameworks across different countries create significant market entry barriers. The EU's IVDR regulations versus FDA's EUA requirements create compliance challenges for manufacturers, with approval processes varying from 3 to 18 months depending on the region. This fragmentation has particularly affected smaller manufacturers attempting to enter multiple markets simultaneously.
Vaccination Rate Impact
Higher vaccination rates in developed nations have somewhat reduced the perceived urgency for frequent testing, particularly in Europe and North America where vaccination rates exceed 70%. This has created market softness in segments previously driven by workplace and institutional testing requirements, with recent data showing a 35% decline in monthly test kit orders from corporate clients in Q2 2023.
Emerging Market Penetration
Developing regions with limited access to PCR facilities represent the fastest growing market segment. Africa and Southeast Asia have shown 420% year-over-year growth in antigen test kit adoption, with international health organizations funding large-scale deployments. The market is projected to grow at 28.7% CAGR in these regions through 2025, with international health organizations prioritizing rapid testing over building expensive PCR infrastructure.
Technological Innovation Pipeline
Next-generation antigen tests with 15-second results and smartphone integration represent the next growth frontier. Recent FDA approvals for AI-powered rapid tests with 98.3% accuracy are opening new market segments for home diagnostics and integrated health monitoring systems, with venture funding in this sector increasing by 187% in the last fiscal year.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
| Rapid Test Cassettes dominate the market due to their ease of use and reliability in producing quick results, while integrated swab-based systems gain traction for comprehensive sampling. |
| By Application |
| Hospitals and clinics remain the primary end-users due to standardized testing protocols, while home care applications show the fastest adoption growth as self-testing becomes more accepted globally. |
| By End User |
| Hospitals and diagnostic centers continue to drive the highest volume through systematic testing programs, while home care users increasingly adopt rapid tests for frequent personal health monitoring and early detection purposes. |
Companies Expand Production Capacity to Meet Surging Global Demand
Roche Diagnostics (Switzerland) maintains market leadership with its extensive distribution network and robust production capacity for SARS-CoV-2 antigen rapid tests, capturing approximately 18% of the global market share in 2023.
Abbott Laboratories (USA) and Siemens Healthineers (Germany) follow closely with their advanced testing technologies and strong presence in North American and European markets, while Becton Dickinson (USA) and QuidelOrtho (USA) have significantly expanded their production facilities to address the pandemic demand.
Qiagen (Germany) and Thermo Fisher Scientific (USA) have invested heavily in R&D for next-generation rapid testing solutions, leveraging their expertise in molecular diagnostics to develop more accurate and faster antigen tests.
Shenzhen Bioeasy Biotechnology (China) and Maccura Biotechnology (China) have captured significant market share in Asia-Pacific through competitive pricing and strategic partnerships with government health agencies, enabling widespread testing in emerging economies.
List of Key COVID-19 Antigen Rapid Test Kits Companies ProfiledThe global market for COVID-19 antigen rapid test kits continues to experience significant growth, driven by the ongoing demand for convenient and accessible testing solutions. Home testing kits have seen a 67% increase in adoption across North America and Europe as consumers seek faster results without clinical visits. Manufacturers are responding with innovations in shelf-stable reagents and user-friendly designs that maintain high accuracy rates comparable to PCR tests in symptomatic individuals.
Other TrendsSupply Chain Optimization
Supply chain improvements have enabled 48% faster distribution of test kits to emerging markets, with particular growth in Southeast Asia and Latin America where regulatory approvals have accelerated. New logistics partnerships between manufacturers and regional distributors are reducing costs by approximately 30% while maintaining cold chain requirements for sensitive components.
International health organizations are collaborating to standardize validation protocols for rapid antigen tests, addressing previous discrepancies in sensitivity thresholds. This harmonization effort is expected to reduce regulatory barriers by up to 40% for manufacturers seeking multi-market approval, particularly benefiting smaller companies with innovative technologies but limited regulatory experience. The streamlined process also addresses the need for standardized quality control in decentralized manufacturing environments.
Production capacity continues to outpace demand in most regions, leading to competitive pricing despite ongoing demand. The average cost per test has decreased by 58% since the initial rollout, with further reductions expected as manufacturing efficiency improves and raw material costs stabilize. Market leaders are investing in automated production lines that can produce up to 5 million units monthly while maintaining 99.8% quality assurance standards.
Regional Analysis: COVID-19 Antigen Rapid Test KitsEurope
The European market demonstrated sophisticated integration of rapid testing into existing healthcare systems rather than creating parallel structures. Countries implemented standardized result reporting through digital platforms, creating valuable data while ensuring privacy. Eastern European nations showed particular efficiency in distributed manufacturing, reducing dependency on Asian imports. Western European markets focused on high-accuracy professional-use tests with advanced reader technologies, while maintaining robust quality assurance systems that became global benchmarks for kit validation and performance monitoring.
Asia-Pacific
The region exhibited the most dynamic market evolution, transitioning from initial import dependency to becoming the dominant global supplier. Manufacturing clusters in China and South Korea achieved unprecedented scale, driving down global prices while improving quality. Southeast Asian nations developed specialized variants for tropical conditions and integrated testing into traditional medicine practices. The region demonstrated the fastest regulatory adaptation, with agencies providing rapid authorization for both domestic and international manufacturers. Distribution networks across diverse geographies created new models for emerging market supply chains.
Latin America
Markets across the region demonstrated remarkable adaptability in implementing testing programs despite infrastructure challenges. Countries developed decentralized distribution systems that reached remote communities through primary healthcare networks. The region showed particular strength in integrating traditional medicine concepts with modern testing, creating culturally appropriate implementation. Brazil's community health agent program became a global model for last-mile delivery, while Mexico's manufacturing initiatives created affordable options without sacrificing quality. The region demonstrated that effective testing penetration depends on community engagement rather than infrastructure alone.
Middle East & Africa
These markets demonstrated that successful implementation depends on adaptation rather than adoption of external models. Islamic nations incorporated testing into religious and community structures rather than clinical settings. African nations developed heat-stable formulations and non-refrigerated distribution, overcoming infrastructure limitations. Gulf states showed that integration into existing systems yields better results than standalone programs. The regions demonstrated that test kit effectiveness depends on cultural acceptance and integration into existing health behaviors rather than technical specifications alone.
This report offers a comprehensive analysis of the global COVID-19 Antigen Rapid Test Kits market, with a focus on the United States market. It covers market size, growth trends, competitive landscape, and key regional insights based on a blend of primary and secondary research.
-> The global COVID-19 antigen rapid test kits market was valued at USD 26.34 billion in 2024 and is projected to decline to USD 789 million by 2031, representing a compound annual growth rate (CAGR) of -40.3% during the forecast period.
-> Abbott Laboratories holds the largest market share at approximately 25%, followed by QuidelOrtho (18%), Roche Diagnostics (15%), and SD Biosensor (12%). Several smaller manufacturers collectively hold the remaining market share.
-> Healthcare institutions account for 60% of sales (hospitals, clinics), while retail pharmacies account for 25%, and online/direct-to-consumer channels account for the remaining 15%. OTC availability increased significantly in 2023.
-> FDA-approved home antigen tests show 85-95% sensitivity when used correctly. However, sensitivity drops to 70-80% for asymptomatic cases. Proper sample collection remains critical for accuracy.
-> Seasonal virus awareness, return-to-office testing mandates, and travel requirements continue to drive demand. However, market growth is offset by reduced COVID-19 incidence rates in most regions.
-> Rapid antigen tests provide results in 15-30 minutes, significantly faster than PCR tests (24-48 hours). This speed makes them ideal for screening applications despite lower sensitivity.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates